Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Jácome, Rodrigo, Campillo-Balderas, José Alberto, Ponce de León, Samuel, Becerra, Arturo, Lazcano, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283245/
https://www.ncbi.nlm.nih.gov/pubmed/32518317
http://dx.doi.org/10.1038/s41598-020-66440-9
_version_ 1783544262540918784
author Jácome, Rodrigo
Campillo-Balderas, José Alberto
Ponce de León, Samuel
Becerra, Arturo
Lazcano, Antonio
author_facet Jácome, Rodrigo
Campillo-Balderas, José Alberto
Ponce de León, Samuel
Becerra, Arturo
Lazcano, Antonio
author_sort Jácome, Rodrigo
collection PubMed
description As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
format Online
Article
Text
id pubmed-7283245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72832452020-06-15 Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic Jácome, Rodrigo Campillo-Balderas, José Alberto Ponce de León, Samuel Becerra, Arturo Lazcano, Antonio Sci Rep Article As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens. Nature Publishing Group UK 2020-06-09 /pmc/articles/PMC7283245/ /pubmed/32518317 http://dx.doi.org/10.1038/s41598-020-66440-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Jácome, Rodrigo
Campillo-Balderas, José Alberto
Ponce de León, Samuel
Becerra, Arturo
Lazcano, Antonio
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_full Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_fullStr Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_full_unstemmed Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_short Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
title_sort sofosbuvir as a potential alternative to treat the sars-cov-2 epidemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283245/
https://www.ncbi.nlm.nih.gov/pubmed/32518317
http://dx.doi.org/10.1038/s41598-020-66440-9
work_keys_str_mv AT jacomerodrigo sofosbuvirasapotentialalternativetotreatthesarscov2epidemic
AT campillobalderasjosealberto sofosbuvirasapotentialalternativetotreatthesarscov2epidemic
AT poncedeleonsamuel sofosbuvirasapotentialalternativetotreatthesarscov2epidemic
AT becerraarturo sofosbuvirasapotentialalternativetotreatthesarscov2epidemic
AT lazcanoantonio sofosbuvirasapotentialalternativetotreatthesarscov2epidemic

Ejemplares similares